Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Squibb Licenses Three of Aureus Pharma’s Databases

NEW YORK (GenomeWeb News) - Aureus Pharma said today that Bristol-Myers Squibb will license three of its databases.
 
Under the agreement, BMS has renewed its license for Aureus’ AurScope GPCR, and it has signed new agreements to license the AurScope Kinase and Ion Channel Knowledge databases as well.
 
Aureus said its databases provide information on drug target classes and other pharma topics, including ADME and drug-drug interactions. This information has been mined from the scientific literature to help researchers design and prioritize experiments, the company said.
 
BMS and Aureus Pharma have been license partners since 2002.
 
Financial terms of the license were not released

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.